OpGen (OPGN) Competitors $3.60 +0.11 (+3.15%) As of 04/8/2025 03:01 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock OPGN vs. CORBF, QIPT, BDSX, EUDA, TOI, XGN, PIII, BNR, ENZ, and CCMShould you be buying OpGen stock or one of its competitors? The main competitors of OpGen include Global Cord Blood (CORBF), Quipt Home Medical (QIPT), Biodesix (BDSX), EUDA Health (EUDA), Oncology Institute (TOI), Exagen (XGN), P3 Health Partners (PIII), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), and Concord Medical Services (CCM). These companies are all part of the "healthcare" industry. OpGen vs. Global Cord Blood Quipt Home Medical Biodesix EUDA Health Oncology Institute Exagen P3 Health Partners Burning Rock Biotech Enzo Biochem Concord Medical Services OpGen (NASDAQ:OPGN) and Global Cord Blood (NYSE:CORBF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Is OPGN or CORBF more profitable? Global Cord Blood has a net margin of 0.00% compared to OpGen's net margin of -1,140.36%. Company Net Margins Return on Equity Return on Assets OpGen-1,140.36% N/A -287.58% Global Cord Blood N/A N/A N/A Does the media favor OPGN or CORBF? In the previous week, OpGen's average media sentiment score of 0.00 equaled Global Cord Blood'saverage media sentiment score. Company Overall Sentiment OpGen Neutral Global Cord Blood Neutral Which has more volatility and risk, OPGN or CORBF? OpGen has a beta of -1.61, meaning that its share price is 261% less volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.64, meaning that its share price is 164% less volatile than the S&P 500. Which has higher valuation & earnings, OPGN or CORBF? Global Cord Blood has higher revenue and earnings than OpGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpGen$2.67M11.25-$32.67MN/AN/AGlobal Cord Blood$196.12M0.71$79.04MN/AN/A Do insiders and institutionals hold more shares of OPGN or CORBF? 2.7% of OpGen shares are held by institutional investors. 43.8% of OpGen shares are held by company insiders. Comparatively, 0.5% of Global Cord Blood shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer OPGN or CORBF? OpGen received 301 more outperform votes than Global Cord Blood when rated by MarketBeat users. CompanyUnderperformOutperformOpGenOutperform Votes30152.35% Underperform Votes27447.65% Global Cord BloodN/AN/A SummaryGlobal Cord Blood beats OpGen on 5 of the 9 factors compared between the two stocks. Remove Ads Get OpGen News Delivered to You Automatically Sign up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPGN vs. The Competition Export to ExcelMetricOpGenMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.08M$2.57B$5.08B$6.91BDividend YieldN/A32.78%5.34%4.23%P/E RatioN/A11.4321.2317.05Price / Sales11.25168.15349.8385.96Price / CashN/A57.5638.1534.64Price / Book-0.314.156.023.66Net Income-$32.67M-$22.21M$3.19B$247.27M7 Day Performance-13.25%23.82%-8.88%-9.80%1 Month Performance263.67%15.86%-6.84%-12.84%1 Year Performance-49.30%5.21%0.58%-10.68% OpGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPGNOpGenN/A$3.60+3.2%N/A-53.8%$30.08M$2.67M0.00100Gap DownHigh Trading VolumeCORBFGlobal Cord BloodN/A$0.90+12.5%N/A-14.8%$109.40M$196.12M0.001,200QIPTQuipt Home Medical1.8139 of 5 stars$2.33+0.4%$6.25+168.2%-51.4%$100.40M$244.72M-13.71800BDSXBiodesix2.6299 of 5 stars$0.63-6.7%$2.95+371.8%-58.4%$91.27M$71.32M-1.60220Positive NewsEUDAEUDA HealthN/A$3.64-0.5%N/A+108.6%$90.14M$3.81M0.002News CoverageTOIOncology Institute0.1984 of 5 stars$1.14flatN/A-15.1%$86.14M$393.41M-1.46660Gap UpXGNExagen4.4462 of 5 stars$3.59-6.5%$7.50+108.9%+172.1%$64.25M$55.64M-3.82220Positive NewsGap DownPIIIP3 Health Partners1.9132 of 5 stars$0.16-4.9%$0.25+52.3%-78.6%$58.88M$1.48B-0.20500BNRBurning Rock BiotechN/A$4.34-3.9%N/A-49.9%$44.50M$515.82M-1.451,390Gap UpENZEnzo BiochemN/A$0.36-16.3%N/A-73.2%$18.92M$29.09M0.00520Analyst ForecastGap UpHigh Trading VolumeCCMConcord Medical ServicesN/A$4.20-3.9%N/A-32.0%$18.24M$471.70M0.00970Analyst ForecastGap Up Remove Ads Related Companies and Tools Related Companies CORBF Competitors QIPT Competitors BDSX Competitors EUDA Competitors TOI Competitors XGN Competitors PIII Competitors BNR Competitors ENZ Competitors CCM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPGN) was last updated on 4/9/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OPGN Stock Free OPGN Stock Alerts